title: Effect of implementing anti-HLA antibody detection by Luminex in the kidney transplant program in Chile.
abstract: The development of new highly sensitive, specific technologies to detect HLA antibodies has allowed a better definition of the profile of non-permitted antigens for patients awaiting kidney transplantation. The use of calculated or virtual panel reactive antibodies (CPRA or vPRA) seeks to improve the prediction of positive crossmatches (XM), but increases the proportion of sensitized patients on the waiting list. In 2008-2009, we implemented detection of antibodies using Luminex technology and applied vPRA since 2009. The objective of this study was to evaluate the impact of these innovations in defecting patient sensitization on kidney transplant waiting lists for deceased donors and among transplanted patients. We analyzed the waiting list for 2007 through 2009 and the first semester of 2010, including the patients transplanted in these periods and the XM with deceased donors. We observed an increase in the mean peak PRA of transplanted patients from 7.2% in 2007 to 17.1% in 2010 (P = .001), and in the proportion of patients transplanted with a peak PRA > 50% from 2.8% in 2007 to 15.7% in 2010 (P = .0001), with no increase in the proportion of this population on the waiting lists. There was a concurrent decrease in positive XM among patients with a peak PRA > 50%. The use of vPRA and Luminex permitted a greater number of transplants of patients with peak PRA > 50% and was a good predictor of a positive XM.
authors.affiliation: Sección Histocompatibilidad, Instituto de Salud Pública de Chile, Santiago, Chile. selgueta@ispch.cl
authors.forename: S
authors.initials: S
authors.lastname: Elgueta
authors.forename: C
authors.initials: C
authors.lastname: Fuentes
authors.forename: M
authors.initials: M
authors.lastname: López
authors.forename: J
authors.initials: J
authors.lastname: Hernández
authors.forename: A
authors.initials: A
authors.lastname: Arenas
authors.forename: M
authors.initials: M
authors.lastname: Jiménez
authors.forename: J G
authors.initials: JG
authors.lastname: Gajardo
authors.forename: H
authors.initials: H
authors.lastname: Rodríguez
authors.forename: C
authors.initials: C
authors.lastname: Labraña
mesh_terms: D000906:Antibodies / Q000737:chemistry*; D002677:Chile; D006084:Graft Rejection / Q000276:immunology; D006085:Graft Survival / Q000276:immunology; D006680:HLA Antigens / Q000276:immunology*; D006648:Histocompatibility / Q000276:immunology; D006650:Histocompatibility Testing; D006801:Humans; D016030:Kidney Transplantation / Q000379:methods*; D051437:Renal Insufficiency / Q000628:therapy; D014019:Tissue Donors; D009927:Tissue and Organ Procurement / Q000379:methods*; D014850:Waiting Lists
chemical_list: D000906:Antibodies; D006680:HLA Antigens